Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial publishing date : 2021 - 09 - 13 save search
Additional Data from Hepion Pharmaceuticals’ Phase 2a ‘AMBITION’ Trial Further Strengthens CRV431 Clinical Profile and Paves Way for Initiation of Phase 2b ‘ASCEND-NASH’ Clinical Program
Published: 2021-09-13 (Crawled : 19:00) - biospace.com/
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: 4.82%
H: 0.57%
C: -3.45%
phase 2 phase 2b nash trial crv431
Galecto Announces First Patient Treated in Phase 2 Trial of Oral Galectin-3 Inhibitor GB1211 in Liver CirrhosisGalecto now has three ongoing Phase 2 clinical trials with three different drug candidates in three high value indications
Published: 2021-09-13 (Crawled : 18:00) - biospace.com/
GLTO | $0.72 4.71% 77K
|
Health Technology
|
| O: 0.0%
H: 2.27%
C: -2.27%
gb1211 phase 2 ongoing clinical trials cirrhosis trials drug liver trial liver cirrhosis galectin-3
MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan
Published: 2021-09-13 (Crawled : 18:00) - biospace.com/
MYMD | $2.54 0.8% 0.79% 18K
|
Manufacturing
|
| O: 1.55%
H: 0.0%
C: -10.69%
phase 2 trial
Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial
Published: 2021-09-13 (Crawled : 14:00) - biospace.com/
ADAP | $0.97 7.97% 7.38% 1.5M
|
Health Technology
|
| O: 9.12%
H: 0.29%
C: -14.22%
trial solid tumors response
DiaMedica Therapeutics Initiates Pivotal Trial of DM199 for the Treatment of Acute Ischemic Stroke
Published: 2021-09-13 (Crawled : 14:00) - biospace.com/
DMAC | $2.46 -1.21% -1.22% 21K
|
Health Technology
|
| O: 1.47%
H: 0.24%
C: -5.06%
treatment stroke trial
IceCure Medical Announces First Peer Reviewed Publication for the 3-Year Interim Analysis of the ICE3 Trial on Cryoablation of Low-Risk, Early-Stage Breast Cancer
Published: 2021-09-13 (Crawled : 14:00) - biospace.com/
ICCM | $1.23 -4.03% 120K
|
Manufacturing
|
| O: 0.97%
H: 0.0%
C: -8.96%
cryo risk cancer breast cancer trial
Leap Therapeutics to Present New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO 2021 Congress
Published: 2021-09-13 (Crawled : 14:00) - biospace.com/
LPTX | $2.81 -5.07% -5.34% 200K
|
Health Technology
|
| O: 28.08%
H: 2.67%
C: -5.35%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.0%
H: 4.26%
C: 3.47%
Emulsifiers Market Size to Reach USD 13.08 Billion in 2028 | Increasing Use of Emulsifiers in Cosmetics Formulations and Rising Use as Industrial Lubricants Are Significant Factors Driving Industry Demand, says Emergen Research
Published: 2021-09-13 (Crawled : 13:00) - prnewswire.com
CLZNY | $14.76 27.55% 310
|
Manufacturing
| Email alert
Add to watchlist
research trial merge
Replacement of Conventional Sub-meters with Smart Sub-meters in Commercial, Industrial Sectors to Drive Electric Sub-meter Market, Says TMR
Published: 2021-09-13 (Crawled : 13:00) - prnewswire.com
HON | News M | $194.27 1.67% 1.64% 3.6M
|
Producer Manufacturing
|
| O: 0.67%
H: 0.62%
C: -0.32%
trial commercialization
ImmunityBio Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with a Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-free in Phase 2/3 Trial
Published: 2021-09-13 (Crawled : 13:00) - nantkwest.com
IBRX | $5.265 7.23% 6.74% 4.6M
|
Manufacturing
|
| O: 0.81%
H: 3.11%
C: -2.01%
media phase 2 phase 2/3 positive cancer trial response bladder
Monopar Expands Phase 2b/3 VOICE Clinical Trial to Europe
Published: 2021-09-13 (Crawled : 13:00) - biospace.com/
MNPR | $0.636 -6.19% -6.6% 33K
|
Health Technology
|
| O: 2.34%
H: 2.28%
C: -9.67%
phase 2 europe phase 2b trial
WillScot Mobile Mini Holdings to Participate in the DA Davidson Diversified Industrials & Services Conference
Published: 2021-09-13 (Crawled : 13:00) - globenewswire.com
WSC | $38.47 1.29% 1.27% 3M
|
Finance
|
| O: 0.98%
H: 1.39%
C: -0.14%
mobile trials trial conference
Anebulo Pharmaceuticals Announces Completion of Manufacturing of ANEB-001 Capsules for Upcoming Phase 2 Clinical Trial
Published: 2021-09-13 (Crawled : 13:00) - biospace.com/
ANEB | $2.85 -7.14% 710
|
Manufacturing
|
| O: 0.33%
H: 1.73%
C: 1.45%
phase 2 trial
Instil Bio Receives IND Clearance to Initiate a Phase 2 Clinical Trial for Patients with Advanced Melanoma
Published: 2021-09-13 (Crawled : 13:00) - biospace.com/
TIL | $10.53 1.15% 1.14% 9.9K
|
Professional, Scientific, and T...
|
| O: -0.32%
H: 5.27%
C: -3.01%
phase 2 trial clearance
Galecto Announces First Patient Treated in Phase 2 Trial of Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis
Published: 2021-09-13 (Crawled : 12:15) - globenewswire.com
GLTO | $0.72 4.71% 77K
|
Health Technology
|
| O: 0.0%
H: 2.27%
C: -2.27%
phase 2 cirrhosis liver trial gb1211 galectin-3 ykl-40
Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
Published: 2021-09-13 (Crawled : 12:00) - zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: 0.0%
H: 1.9%
C: -0.45%
phase 3 trial syndros zygel
Dana Upgrades Power Density, Torque Range of Brevini™ Helical and Bevel Helical Gearboxes for Industrial Mining Applications
Published: 2021-09-13 (Crawled : 12:00) - prnewswire.com
DAN | $12.15 1.17% -0.25% 1.9M
|
Producer Manufacturing
|
| O: 2.98%
H: 2.06%
C: 1.83%
trial application
BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough
Published: 2021-09-13 (Crawled : 12:00) - biospace.com/
BLU | $14.74 0.03% 0
|
Health Technology
|
| O: 20.66%
H: 8.88%
C: 1.06%
phase 2 positive chronic cough phase 2b trial blu-5937
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Durable Overall Survival at Three Years Compared to Chemotherapy in First-Line Unresectable Malignant Pleural Mesothelioma in Phase 3 CheckMate -743 Trial
Published: 2021-09-13 (Crawled : 12:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.54%
H: 0.06%
C: -0.99%
therapy phase 3 trial nivolumab
Syros to Present New Data from Phase 1 Clinical Trial of SY-5609 in Oral Presentation at ESMO Congress 2021
Published: 2021-09-13 (Crawled : 12:00) - biospace.com/
SYRS | $4.54 -3.81% -3.96% 260K
|
Health Technology
|
| O: 0.0%
H: 6.9%
C: 3.16%
presentation phase 1 trial phase 2 phase 3
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.